114 related articles for article (PubMed ID: 8826617)
1. Metoclopramide as a modulator of cisplatin: effects on pharmacokinetcs and cisplatin-DNA adducts in tumor and normal tissue.
Johnsson A; Kjellén E; Wennerberg J; Pero R
Anticancer Drugs; 1996 Jun; 7(4):483-8. PubMed ID: 8826617
[TBL] [Abstract][Full Text] [Related]
2. Expression of GADD153 in tumor cells and stromal cells from xenografted tumors in nude mice treated with cisplatin: correlations with cisplatin-DNA adducts.
Johnsson A; Strand C; Los G
Cancer Chemother Pharmacol; 1999; 43(4):348-52. PubMed ID: 10071988
[TBL] [Abstract][Full Text] [Related]
3. Metoclopramide enhances the effect of cisplatin on xenografted squamous cell carcinoma of the head and neck.
Kjellén E; Wennerberg J; Pero R
Br J Cancer; 1989 Feb; 59(2):247-50. PubMed ID: 2930689
[TBL] [Abstract][Full Text] [Related]
4. Dose schedule evaluation of metoclopramide as a potentiator of cisplatin and carboplatin treatments of xenografted squamous cell carcinomas of the head and neck.
Lybak S; Wennerberg J; Kjellén E; Pero RW
Anticancer Drugs; 1991 Aug; 2(4):375-82. PubMed ID: 1797194
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts.
Johnsson A; Olsson C; Nygren O; Nilsson M; Seiving B; Cavallin-Stahl E
Cancer Chemother Pharmacol; 1995; 37(1-2):23-31. PubMed ID: 7497593
[TBL] [Abstract][Full Text] [Related]
6. A topographic study on the distribution of cisplatin in xenografted tumors on nude mice.
Johnsson A; Cavallin-Stahl E
Anticancer Drugs; 1996 Jan; 7(1):70-7. PubMed ID: 8742101
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo.
Welters MJ; Fichtinger-Schepman AM; Baan RA; Jacobs-Bergmans AJ; Kegel A; van der Vijgh WJ; Braakhuis BJ
Br J Cancer; 1999 Jan; 79(1):82-8. PubMed ID: 10408697
[TBL] [Abstract][Full Text] [Related]
8. Metoclopramide enhances the effect of ionizing radiation on xenografted squamous cell carcinoma of the head and neck.
Lybak S; Kjellén E; Wennerberg J; Pero R
Int J Radiat Oncol Biol Phys; 1990 Dec; 19(6):1419-24. PubMed ID: 2262366
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice.
Korst AE; Boven E; van der Sterre ML; Fichtinger-Schepman AM; van der Vijgh WJ
Eur J Cancer; 1998 Feb; 34(3):412-6. PubMed ID: 9640232
[TBL] [Abstract][Full Text] [Related]
10. Biochemical modulation of chemotherapy and radiotherapy in head and neck cancer.
Wennerberg J; Kjellén E; Lybak S; Rydell R; Pero R
Anticancer Res; 1993; 13(6B):2501-6. PubMed ID: 8135490
[TBL] [Abstract][Full Text] [Related]
11. Amifostine as a protector against cisplatin-induced toxicity in nude mice.
Johnsson A; Wennerberg J
Acta Oncol; 1999; 38(2):247-53. PubMed ID: 10227448
[TBL] [Abstract][Full Text] [Related]
12. Circadian variations in cell cycle phase distribution in a squamous cell carcinoma xenograft; effects of cisplatin and fluorouracil treatment.
Rydell R; Wennerberg J; Willen R
In Vivo; 1990; 4(6):385-9. PubMed ID: 2103378
[TBL] [Abstract][Full Text] [Related]
13. Effects of intralesional injection of cisplatin on squamous cell carcinoma and normal tissue of mice.
Landrito JE; Yoshiga K; Sakurai K; Takada K
Anticancer Res; 1994; 14(1A):113-8. PubMed ID: 8166436
[TBL] [Abstract][Full Text] [Related]
14. Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT).
Hoebers FJ; Pluim D; Verheij M; Balm AJ; Bartelink H; Schellens JH; Begg AC
Int J Cancer; 2006 Aug; 119(4):750-6. PubMed ID: 16550603
[TBL] [Abstract][Full Text] [Related]
15. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells.
Rietbroek RC; van de Vaart PJ; Haveman J; Blommaert FA; Geerdink A; Bakker PJ; Veenhof CH
J Cancer Res Clin Oncol; 1997; 123(1):6-12. PubMed ID: 8996534
[TBL] [Abstract][Full Text] [Related]
16. Effects of amifostine on cisplatin induced DNA adduct formation and toxicity in malignant glioma and normal tissues in rat.
Bergström P; Johnsson A; Bergenheim T; Henriksson R
J Neurooncol; 1999 Mar; 42(1):13-21. PubMed ID: 10360475
[TBL] [Abstract][Full Text] [Related]
17. DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines.
Delmastro DA; Li J; Vaisman A; Solle M; Chaney SG
Cancer Chemother Pharmacol; 1997; 39(3):245-53. PubMed ID: 8996528
[TBL] [Abstract][Full Text] [Related]
18. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
O'Neill CF; Hunakova L; Kelland LR
Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
[TBL] [Abstract][Full Text] [Related]
19. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.
Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Zuhowski EG; Pluim D; Joseph E; Hamburger DR; Working PK; Colbern G; Tonda ME; Potter DM; Eiseman JL
Cancer Chemother Pharmacol; 2004 Apr; 53(4):329-36. PubMed ID: 14673619
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a method for quantitative immunohistochemical analysis of cisplatin-DNA adducts in tissues from nude mice.
Johnsson A; Olsson C; Anderson H; Cavallin-Ståhl E
Cytometry; 1994 Oct; 17(2):142-50. PubMed ID: 7835164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
